Daniel Collins

GW Pharmaceuticals’ (GWPH) net income was -$295.2 million in fiscal 2018—compared to -$170.5 million in fiscal 2017.

On January 28, Cara Therapeutics’ (CARA) stock price closed at $14.82, which is an ~4.02% discount compared to its previous close.

Today, on the OTC markets, iAnthus Capital Holdings stock (ITHUF) is trading ~3.63% above yesterday’s closing price of $4.84.

On January 25, Charlotte’s Web Holdings’ (CWBHF) stock price closed at $14.41, ~4.87% higher than its closing price of $13.74 on January 24 and ~11% higher than its closing price of $6.21 on January 18.

On January 25, CannTrust Holdings’ (CNTTF) stock price closed at $6.87, ~5.19% higher than its closing price of $6.53 on January 24 and ~11% higher than its closing price of $6.21 on January 18.

On January 25, Innovative Industrial Properties (IIPR) stock price closed at $59.94, ~3.52% higher than its closing price of $57.90 on January 24 and ~10% higher compared than its closing price of $54.32 on January 18.

On January 25, on the OTC markets, Auxly Cannabis Group’s stock price closed at $0.72, which is ~6.75% higher than its close of $0.67 on January 24 and reflects ~8% growth YTD (year-to-date).

Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.

On January 24, Cannabis Strategic Ventures stock closed at $1.69—an ~8.33% rise compared to its closing price of $203.66 on January 23.

In the first nine months of 2018, Cara Therapeutics (CARA) reported a net income and EPS of -$53.4 million and -$1.54, respectively.

In the first nine months of 2018, Cara Therapeutics (CARA) generated revenues of $7.9 million.

Cara Therapeutics’ (CARA) stock price reached $15.35 on January 18—compared to $13.00 when the market closed on December 31.

Today, Johnson & Johnson (JNJ) released its fourth-quarter and 2018 financial results.

On January 18, iAnthus Capital Holdings stock closed at $4.7, ~5.18% higher than its close of $4.5 on January 17, 2019.

Charlotte’s Web Holdings reached $13.04 on January 18, which represents an ~18% YTD increase.

Today, Aptinyx (APTX) is trading at $5.26, which is a ~70.5% decline from yesterday’s closing price of $17.83.

Today, Boston Scientific (BSX) is trading at $36.76, which is a ~4.11% increase from yesterday’s closing price.

Green Thumb Industries reported net revenue of $17.17 million in the third quarter of 2018. What do analysts expect for the fourth quarter?

In January, Green Thumb announced that it had entered into a definitive agreement to acquire Advanced Grow Labs for a value of $80.0 million.

On January 11, Green Thumb Industries (GTBIF) stock closed at $12.05, up ~15% from its previous week’s closing price.

In the first nine months of 2018, INSYS Therapeutics’ (INSY) net income and diluted EPS amounted to $78.1 million and $1.06, respectively.

In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.

On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of markets on December 31.

GW Pharmaceuticals completed three phase 3 trials in Europe with Sativex (nabiximos), which all produced positive results.

In fiscal 2018, GW Pharmaceuticals (GWPH) reported net income and EPS of -$295.2 million and -$0.88, respectively.

In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.

GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products.

On January 9, Globus Medical was trading at a stock price of $43.79, which is an ~9.91% rise from its closing price of $39.84 on January 8.

On January 8, CannTrust Holdings’ (CNTTF) stock price closed at $5.63, which is ~3.04% growth from its close of $5.47 on January 7.

Analysts expect Auxly Cannabis to report a net income of -40.08 million Canadian dollars in fiscal 2018.

Auxly Cannabis’ stock price closed at $0.67 on January 7, which is ~52% growth from its 52-week low of $0.44 on December 24.

On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.

On January 7, Neurocrine Biosciences (NBIX) stock rose ~9.57% to reach $81.86 from its prior close of $74.71.

In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.

In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.

On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.

On January 7, Sage Therapeutics presented the results of the Phase 3 ROBIN trial. SAGE-217 met the clinical trial’s primary and secondary endpoints.

On January 4, Portola Pharmaceuticals stock closed at $19.38, an ~8.09% increase from its prior close of $17.93 on January 3,

Of the ten analysts tracking Epizyme in January, four of them recommend a “strong buy,” while another four analysts recommend a “buy.”

The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.

Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.

Today, Bristol-Myers Squibb (BMY) is trading at $45.85, ~11.86% lower than its previous day’s closing price.

In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.

Tandem Diabetes Care (TNDM) stock grew from $2.36 on December 29, 2017, to reach $37.31 at the close of market on December 28, 2018, an increase of ~1,481% this year.

In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.

In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.

Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.

In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.

On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.

Pfizer’s (PFE) Prevnar (or Prevenar) 13 is used to prevent pneumococcal diseases.

In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.7 billion from $4.4 billion.

In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million.

In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million.

In the first nine months of this year, Pfizer’s (PFE) Ibrance revenue grew 24% YoY (year-over-year) to $3.0 billion from $2.4 billion.

The new joint venture between GlaxoSmithKline and Pfizer will enable GlaxoSmithKline to strengthen its consumer healthcare business.

Pfizer’s (PFE) consumer health business generated revenues of $2.6 billion during the first nine months in 2018.

On December 19, GlaxoSmithKline (GSK) and Pfizer (PFE) entered into an agreement to combine both of their consumer health businesses.

Allergan (AGN) is trading at $135.98, which is a ~7.47% decline from its close of $146.76 on December 18.

On December 17, Pfizer’s stock price closed at $43.11, which is an ~1.58% decline from its close of $43.80 on December 14.

Pfizer’s net revenues were $39.7 billion in the first nine months of 2018—compared to $38.8 billion during the same period in 2017.

On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62.

Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11.

Medtronic’s (MDT) Spine Therapies generated revenues of $1.3 billion in the first half of fiscal 2019.

Medtronic’s Restorative Therapies Group consists of Spine, Brain, Specialty and Pain therapies.

Medtronic’s MITG segment generated revenues of $4.1 billion in the first half of fiscal 2019 compared to $4.4 billion in the first half of fiscal 2018.

Medtronic’s (MDT) Cardiac Rhythm & Heart Failure segment generated revenues of $1.47 billion in the second quarter of fiscal 2019.

Medtronic’s (MDT) Cardiac & Vascular Group generated revenues of $2.9 billion in the second quarter of fiscal 2019 compared to $2.8 billion in the second quarter of fiscal 2018.

Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018.

Of the 27 analysts tracking Medtronic in December 2018, six of them recommended a “strong buy,” while nine analysts recommended a “buy.”

Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10.

On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.

On December 3, GlaxoSmithKline (GSK) entered into an agreement with Tesaro (TSRO). GlaxoSmithKline will acquire Tesaro for ~$5.1 billion.

On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.

Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29.

On November 29, IQVIA Holdings’ (IQV) stock price closed at $124.95, which is ~6% growth from its close of $117.73 on November 23.

On November 29, Express Scripts Holding’s stock price closed at $101.22, which is ~5% growth from the close of $96.81 on November 23.

On November 29, United Health Group’s (UNH) stock price closed at $282.55, which is ~8% growth from its close of $261.62 on November 23.

BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.

On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.

On November 26, Illumina (ILMN) stock closed at $316.79, a rise of ~2.03% from its previous close of $310.50 on November 23.

On November 26, Abiomed (ABMD) stock closed at $311.15, a ~3.92% rise from its previous day’s close of $299.41 on November 23.

On November 23, Dexcom (DXCM) stock closed at $124.28, a rise of ~2.20% from its previous day’s close of $121.61.

Boston Scientific stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23.

Intuitive Surgical’s stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018.

On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.

On November 21, Mirati Therapeutics (MRTX) stock closed at $40.24, a ~2.57% fall from its previous day’s close of $41.30.

On November 21, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.95, a ~5.28% rise from its previous day’s close of $12.30.

Endocyte (ECYT) stock rose from $4.28 at the close of market on December 29, 2017, to $23.60 at the close of market on November 20, 2018.

On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA).

On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.

On November 19, GlaxoSmithKline’s stock price closed at $40.83, which represents ~1.21% growth from its close of $40.34 on November 16.

On November 16, Eli Lilly’s (LLY) stock price closed at $113.83, which represents ~1.45% growth from its close of $112.20 on November 15.

On November 16, Merck’s stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15.

Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth YTD.

Bausch Health’s (BHC) Diversified segment consists of neurology, generics, dentistry, and other drugs.

Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017.

Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.

On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.

Jazz Pharmaceuticals’ Defitelio generated revenues of $36.2 million in the third quarter—compared to $31.2 million in the third quarter of 2017.